* Puma Biotechnology Inc PBYI.OQ PBYI.O is expected
to show a
fall in quarterly revenue when it reports results on May 2 for
the period ending March 31 2024
* The Los Angeles California-based company is expected to
report
a 22.2% decrease in revenue to $41.05 million from $52.78
million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Puma Biotechnology Inc
is for
a loss of 22 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Puma
Biotechnology Inc is $4.00, below its last closing price
of $5.02.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.32 0.30 0.26 Missed -13.2
Sep. 30 2023 0.08 0.08 0.12 Beat 56.5
Jun. 30 2023 0.01 0.01 0.05 Beat 566.7
Jan. 1 0001 -0.07 -0.07 0.03 Beat 142.9
Dec. 0.05 0.05 -0.12 Missed -340
31 2022
Jan. 1 0001 -0.06 -0.05 -0.01 Beat 81.8
Jun. 30 2022 0.01 0.01 0.21 Beat 1,958.
8
Mar. 31 2022 -0.16 -0.17 -0.08 Beat 51.8
This summary was machine generated April 30 at 22:19 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)